Abstract
Herpes simplex virus type 2 (HSV-2) develops an annual incidence of 2.3 million people worldwide, which can lead to life-long latent infections, asymptomatic and reactivations and with occasional symptomatic episodes causing ulcerative lesions in the genitalia and naus.
Highlights
Herpes simplex virus type 2 (HSV-2) develops an annual incidence of 2.3 million people worldwide, which can lead to life-long latent infections, asymptomatic and reactivations [1,2], and with occasional symptomatic episodes causing ulcerative lesions in the genitalia and naus [3]
The safety and application prospects of DNA vaccines are unquestionable, clinical trial of the HSV-2 vaccine has shown that its effectiveness in the total population is only 38% [10], and it is still ineffective for most populations [11,12]
HSV-2 glycoprotein D (gD) and gB DNA vaccine can have a certain preventive effect on HSV-1 strains, but only in HSV-1 and HSV2 serotype double-negative population to prevent 73% of people infected with HSV-2, and was invalid in protect men [12]
Summary
Yan Yan1*, Xu Wang, Renfang Chen1* 1Infection and Immunity Laboratory, The Fifth People’s Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China 2Center of Clinical Laboratory, The Fifth People’s Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China. ASCs: IgA Ab-Secreting Cells; IRES: Internal Ribosome Entry Site; IZ: GCN4-based Isoleucine Zipper Trimerization Domain; s.c.: subcutaneous(ly); i.vag.: intravaginal(ly); MLN: Mesenteric Lymph Node; MLNL: Mesenteric Lymph Node Lymphocyte
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
